{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:39:30Z","timestamp":1770885570606,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00117-022-01072-w","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T15:02:56Z","timestamp":1663340576000},"page":"875-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Onkologische Theranostik in der Nuklearmedizin","Oncological theranostics in nuclear medicine"],"prefix":"10.1007","volume":"62","author":[{"given":"Christina","family":"Laschinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Sandach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"1072_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094597","author":"N Vahidfar","year":"2021","unstructured":"Vahidfar\u00a0N, Aghanejad, Ayuob, Ahmadzadehfar, Hojjat, Farzanehfar\u00a0S, Eppard\u00a0E (2021) Theranostic advances in breast cancer in nuclear medicin. IJMS. https:\/\/doi.org\/10.3390\/ijms22094597","journal-title":"IJMS"},{"issue":"1","key":"1072_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40658-017-0182-7","volume":"4","author":"FH Fahey","year":"2017","unstructured":"Fahey\u00a0FH, Grant\u00a0FD, Thrall\u00a0JH (2017) Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys 4(1):15. https:\/\/doi.org\/10.1186\/s40658-017-0182-7","journal-title":"EJNMMI Phys"},{"issue":"14","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","volume":"132","author":"SM Seidlin","year":"1946","unstructured":"Seidlin\u00a0SM, Marinelli\u00a0LD, Oshry\u00a0E (1946) Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132(14):838\u2013847. https:\/\/doi.org\/10.1001\/jama.1946.02870490016004","journal-title":"JAMA"},{"issue":"12","key":"1072_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11654-019-00192-5","volume":"14","author":"P Sandach","year":"2019","unstructured":"Sandach\u00a0P, Fendler\u00a0WP, Herrmann\u00a0K (2019) Theranostik von soliden Tumoren: Renaissance eines alten Konzepts. Best Pract Onkol 14(12):526\u2013534. https:\/\/doi.org\/10.1007\/s11654-019-00192-5","journal-title":"Best Pract Onkol"},{"issue":"1091","key":"1072_CR5","doi-asserted-by":"publisher","first-page":"20180136","DOI":"10.1259\/bjr.20180136","volume":"91","author":"PS Choudhury","year":"2018","unstructured":"Choudhury\u00a0PS, Gupta\u00a0M (2018) Differentiated thyroid cancer theranostics: radioiodine and beyond. BJR 91(1091):20180136. https:\/\/doi.org\/10.1259\/bjr.20180136","journal-title":"BJR"},{"issue":"2466","key":"1072_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.95.2466.362","volume":"95","author":"AS Keston","year":"1942","unstructured":"Keston\u00a0AS, Ball\u00a0RP, Frantz\u00a0VK, Palmer\u00a0WW (1942) Storage of radioactive iodine in A metastasis from thyroid carcinoma. Science 95(2466):362\u2013363. https:\/\/doi.org\/10.1126\/science.95.2466.362","journal-title":"Science"},{"issue":"10","key":"1072_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3275\/8998","volume":"36","author":"Y Fang","year":"2013","unstructured":"Fang\u00a0Y, Ding\u00a0Y, Guo\u00a0Q, Xing\u00a0J, Long\u00a0Y, Zong\u00a0Z (2013) Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses. J\u00a0Endocrinol Invest 36(10):896\u2013902. https:\/\/doi.org\/10.3275\/8998","journal-title":"J Endocrinol Invest"},{"key":"1072_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","volume":"130","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann\u00a0MA, Wieler\u00a0HJ, Baues\u00a0C, Kuntz\u00a0NJ, Richardsen\u00a0I, Schreckenberger\u00a0M (2019) The impact of 68ga-PSMA PET\/CT and PET\/MRI on the management of prostate cancer. Urology 130:1\u201312. https:\/\/doi.org\/10.1016\/j.urology.2019.04.004","journal-title":"Urology"},{"issue":"3","key":"1072_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin\u00a0ME, Pavel\u00a0M, \u0106wik\u0142a\u00a0JB, Phan\u00a0AT, Raderer\u00a0M, Sedl\u00e1\u010dkov\u00e1\u00a0E et\u00a0al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N\u00a0Engl J Med 371(3):224\u2013233. https:\/\/doi.org\/10.1056\/NEJMoa1316158","journal-title":"N Engl J Med"},{"issue":"28","key":"1072_CR10","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke\u00a0A, M\u00fcller\u00a0H\u2011H, Schade-Brittinger\u00a0C, Klose\u00a0K\u2011J, Barth\u00a0P, Wied\u00a0M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a\u00a0report from the PROMID Study Group. J\u00a0Clin Oncol 27(28):4656\u20134663. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"issue":"11","key":"1072_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das\u00a0S, Al-Toubah\u00a0T, El-Haddad\u00a0G, Strosberg\u00a0J (2019) 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 13(11):1023\u20131031. https:\/\/doi.org\/10.1080\/17474124.2019.1685381","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"1072_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg\u00a0J, El-Haddad\u00a0G, Wolin\u00a0E, Hendifar\u00a0A, Yao\u00a0J, Chasen\u00a0B et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N\u00a0Engl J Med 376(2):125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"issue":"10","key":"1072_CR13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg\u00a0J, Kunz\u00a0PL, Hendifar\u00a0A, Yao\u00a0J, Bushnell\u00a0D, Kulke\u00a0MH et al (2020) Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1\u00a0study. Eur J Nucl Med Mol Imaging 47(10):2372\u20132382. https:\/\/doi.org\/10.1007\/s00259-020-04709-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1072_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman\u00a0MS, Violet\u00a0J, Hicks\u00a0RJ, Ferdinandus\u00a0J, Thang\u00a0SP, Akhurst\u00a0T et al (2018) 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a\u00a0single-centre, single-arm, phase 2\u00a0study. Lancet Oncol 19(6):825\u2013833. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0","journal-title":"Lancet Oncol"},{"key":"1072_CR15","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie (2018) S2-Leitlinie Neuroendokrine Tumore. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-026l_S2k_Neuroendokrine_Tumore_2018-07.pdf. Zugegriffen: 11. Jan. 2022"},{"issue":"1","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-019-04524-z","volume":"47","author":"W Cytawa","year":"2020","unstructured":"Cytawa\u00a0W, Seitz\u00a0AK, Kircher\u00a0S, Fukushima\u00a0K, Tran-Gia\u00a0J, Schirbel\u00a0A et al (2020) 68Ga-PSMA I&T PET\/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging 47(1):168\u2013177. https:\/\/doi.org\/10.1007\/s00259-019-04524-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1072_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler\u00a0WP, Calais\u00a0J, Eiber\u00a0M, Flavell\u00a0RR, Mishoe\u00a0A, Feng\u00a0FY et al (2019) Assessment of 68ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5(6):856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096","journal-title":"JAMA Oncol"},{"issue":"7","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2967\/jnumed.118.220855","volume":"60","author":"N-S Schmidt-Hegemann","year":"2019","unstructured":"Schmidt-Hegemann\u00a0N\u2011S, Eze\u00a0C, Minglun\u00a0L, Rogowski\u00a0P, Schaefer\u00a0C, Stief\u00a0C et al (2019) Impact of 68ga-PSMA PET\/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis. J\u00a0Nucl Med 60(7):963\u2013970. https:\/\/doi.org\/10.2967\/jnumed.118.220855","journal-title":"J Nucl Med"},{"key":"1072_CR19","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e.\u202fV. (DGU) (2021) S3-Leitlinie Prostatakarzinom. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Prostatatkarzinom\/Version_6\/LL_Prostatakarzinom_Langversion_6.0.pdf. Zugegriffen: 02. Mai 2022"},{"issue":"7","key":"1072_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.2967\/jnumed.120.258533","volume":"62","author":"H Treiber","year":"2021","unstructured":"Treiber\u00a0H, K\u00f6nig\u00a0A, Neesse\u00a0A, Richter\u00a0A, Sahlmann\u00a0CO, Strauss\u00a0A (2021) Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer. J\u00a0Nucl Med 62(7):1016\u20131019. https:\/\/doi.org\/10.2967\/jnumed.120.258533","journal-title":"J Nucl Med"},{"issue":"6","key":"1072_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet\u00a0J, Shahneen\u00a0S, Iravani\u00a0A, Ferdinandus\u00a0J, Thang\u00a0S\u2011P, Kong\u00a0G et al (2020) Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J\u00a0Nucl Med 61(6):857\u2013865. https:\/\/doi.org\/10.2967\/jnumed.119.236414","journal-title":"J Nucl Med"},{"issue":"12","key":"1072_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN, Fizazi\u00a0K, Herrmann\u00a0K, Rahbar\u00a0K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"1072_CR23","doi-asserted-by":"publisher","DOI":"10.1055\/a-1650-9995","author":"M Miederer","year":"2021","unstructured":"Miederer\u00a0M (2021) Alpha emittierende Nuklide f\u00fcr nuklearmedizinische Theranostik. Nuklearmedizin. https:\/\/doi.org\/10.1055\/a-1650-9995","journal-title":"Nuklearmedizin"},{"issue":"3","key":"1072_CR24","doi-asserted-by":"publisher","first-page":"e0116683","DOI":"10.1371\/journal.pone.0116683","volume":"10","author":"F Liu","year":"2015","unstructured":"Liu\u00a0F, Qi\u00a0L, Liu\u00a0B, Liu\u00a0J, Zhang\u00a0H, Che\u00a0D et al (2015) Fibroblast activation protein overexpression and clinical implications in solid tumors: a\u00a0meta-analysis. PLoS ONE 10(3):e116683. https:\/\/doi.org\/10.1371\/journal.pone.0116683","journal-title":"PLoS ONE"},{"issue":"9","key":"1072_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev\u00a0A, Lindner\u00a0T, Mier\u00a0W, Debus\u00a0J, Altmann\u00a0A, J\u00e4ger\u00a0D et al (2018) A tumor-imaging method targeting cancer-associated fibroblasts. J\u00a0Nucl Med 59(9):1423\u20131429. https:\/\/doi.org\/10.2967\/jnumed.118.210435","journal-title":"J Nucl Med"},{"issue":"8","key":"1072_CR26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen\u00a0H, Pang\u00a0Y, Jingxun\u00a0W, Liang\u00a0Z, Bing\u00a0H, Wu\u00a0J et al (2020a) Comparison of 68GaGa-DOTA-FAPI-04 and 18F FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47(8):1820\u20131832. https:\/\/doi.org\/10.1007\/s00259-020-04769-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1072_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/RLU.0000000000003000","volume":"45","author":"H Chen","year":"2020","unstructured":"Chen\u00a0H, Zhao\u00a0L, Ruan\u00a0D, Sun\u00a0L, Lin\u00a0Q (2020b) 68ga-FAPI PET\/CT improves therapeutic strategy by detecting a\u00a0second primary malignancy in a\u00a0patient with rectal cancer. Clin Nucl Med 45(6):468\u2013470. https:\/\/doi.org\/10.1097\/RLU.0000000000003000","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1072_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel\u00a0FL, Kratochwil\u00a0C, Lindner\u00a0T, Marschalek\u00a0MM, Loktev\u00a0A, Lehnert\u00a0W et al (2019) 68ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J\u00a0Nucl Med 60(3):386\u2013392. https:\/\/doi.org\/10.2967\/jnumed.118.215913","journal-title":"J Nucl Med"},{"issue":"7","key":"1072_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/RLU.0000000000003056","volume":"45","author":"Y Pang","year":"2020","unstructured":"Pang\u00a0Y, Hao\u00a0B, Qihang\u00a0S, Long\u00a0S, Haojun\u00a0C (2020a) Comparison of 68ga-FAPI and 18F-FDG PET\/CT in a\u00a0patient with cholangiocellular carcinoma: a case report. Clin Nucl Med 45(7):566\u2013567. https:\/\/doi.org\/10.1097\/RLU.0000000000003056","journal-title":"Clin Nucl Med"},{"issue":"11","key":"1072_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/RLU.0000000000003263","volume":"45","author":"Y Pang","year":"2020","unstructured":"Pang\u00a0Y, Zhao\u00a0L, Haojun\u00a0C (2020b) 68ga-FAPI outperforms 18F-FDG PET\/CT in identifying bone metastasis and peritoneal carcinomatosis in a\u00a0patient with metastatic breast cancer. Clin Nucl Med 45(11):913\u2013915. https:\/\/doi.org\/10.1097\/RLU.0000000000003263","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1072_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil\u00a0C, Flechsig\u00a0P, Lindner\u00a0T, Abderrahim\u00a0L, Altmann\u00a0A, Mier\u00a0W et al (2019) 68ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J\u00a0Nucl Med 60(6):801\u2013805. https:\/\/doi.org\/10.2967\/jnumed.119.227967","journal-title":"J Nucl Med"},{"key":"1072_CR32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262468","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus\u00a0J, Fragoso Costa\u00a0P, Kessler\u00a0L, Weber\u00a0M, Hirmas\u00a0N, Kostbade\u00a0K et al (2021) Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a\u00a0case series of nine patients. J\u00a0Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.121.262468","journal-title":"J Nucl Med"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-022-01072-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-022-01072-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-022-01072-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T10:05:56Z","timestamp":1664359556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-022-01072-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1007\/s00117-022-01072-w","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"16 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Laschinsky<\/b>: A.\u00a0Finanzielle Interessen: C.\u00a0Laschinsky gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin in der Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen. <b>K.\u00a0Herrmann<\/b>: A.\u00a0Finanzielle Interessen: Bayer: Referent und Berater (2017 und fr\u00fcher), Sirtex: Referent (2017), Adacap\/Novartis: Berater, Referent (aktuell), Curium: Berater (2017 und aktuell), Endocyte: Berater (2017), BTG: Referent und Berater (aktuell), IPSEN: Berater (aktuell), Siemens Healthineers: Referent (aktuell), GE Healthcare: Referent (2018), Amgen: Berater (aktuell), Janssen: Berater (aktuell), Theragnostics: Berater (aktuell), Aktis Oncology: Berater (aktuell).\u00a0\u2013 Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: SOFIE Biosciences (<\u202f1\u202f%), Theragnostics (<\u202f1\u202f%), Aktis Oncology (<\u202f1\u202f%).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Klinikleiter, Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen, Essen | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Nuklearmedizin (DGN), Deutsche Gesellschaft f\u00fcr Endokrinologie (DGE), European Association of Nuclear Medicine (EANM), European Society for Molecular Imaging (ESMI), European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), Society of Nuclear Medicine and Molecular Imaging (SNMMI) | Gesch\u00e4ftsf\u00fchrer Nuklearmedizin Interaktion GmbH, Vorsitzender EANM Oncology and Theranostics Committee. <b>W.\u00a0Fendler<\/b>: A.\u00a0Finanzielle Interessen: Honorare von SOFIE Biosciences und Bayer (Forschungsf\u00f6rderung).\u00a0\u2013 Honorare von Janssen (Vortragsredner), Bayer (Vortragsredner).\u00a0\u2013 Honorare von Janssen (Berater), Calyx (Berater), Bayer (Berater).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt, Translationale und Onkologische Forschung, Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen, Hufelandstra\u00dfe\u00a055, 45147 Essen. <b>M.\u00a0Nader<\/b>: A.\u00a0Finanzielle Interessen: M.\u00a0Nader gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitung Radiopharmazie, Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen, Hufelandstra\u00dfe\u00a055, 45147 Essen. <b>H.\u00a0Lahner<\/b>: A.\u00a0Finanzielle Interessen: Honorar f\u00fcr Vortr\u00e4ge: Fa. AAA.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt an der Klinik f\u00fcr Endokrinologie, Diabetologie und Stoffwechsel, Universit\u00e4tsklinikum Essen, Universit\u00e4t Duisburg-Essen, Endokrines Tumorzentrum am Westdeutschen Tumorzentrum (WTZ) mit Exzellenzzentrum der European Neuroendocrine Tumor Society (ENETS), Referenzzentrum der Europ\u00e4ischen Union | European Reference Network on Rare Endocrine Conditions (ENDO-ERN) und European Reference Network on Rare Adult Solid Cancers (EURACAN), DDG Diabeteszentrum. | Mitgliedschaften: ENETS, Deutsche Gesellschaft f\u00fcr Endokrinologie (DGE), European Society of Endocrinology (ESE), Deutsche Diabetes Gesellschaft (DDG), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Gesellschaft f\u00fcr Andrologie (DGA). <b>B.\u00a0Hadaschik<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Astellas, AstraZeneca, Bayer, BMS, Janssen.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: AAA (Advanced Accelerator Applications)\/Novartis, ABX, Amgen, Lightpoint Medical LTD, Janssen. MSD, Pfizer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum Essen, Facharzt f\u00fcr Urologie | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie (DGU), European Association of Urology (EAU), Soci\u00e9t\u00e9 Internationale d\u02bcUrologie (SIU), World Urological Oncology Federation (WUOF), S3-Leitlinie Prostatakarzinom, Arbeitskreis f\u00fcr Fokale und Mikrotherapie (AKFM). <b>P.\u00a0Sandach<\/b>: A.\u00a0Finanzielle Interessen: Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: 2021 Berater f\u00fcr Advanced Accelerator Applications (AAA).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt\/wissenschaftlicher Mitarbeiter, Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}